# A semaglutide plateau: what to review before switching

A pause in weight change is a reason to review the treatment, not an automatic reason to switch to tirzepatide.

Canonical: https://velri.co/blog/stalled-on-semaglutide-what-provider-reviews-before-switching-dual-action
Publisher: Velri (https://velri.co/about)
Published: 2026-06-16
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A period without further weight loss does not automatically mean semaglutide has stopped helping or that tirzepatide is the next step. Weight-management treatment is reviewed for benefit, tolerability and the person's broader health, not one scale reading. [1]

## Establish what has actually changed

A review is more useful with a dated trend than a remembered lowest weight. Treatment duration, prescribed changes, missed doses and interruptions in supply help describe the course of treatment.

The goal is an accurate account, not a test of willpower. A medication plan that has been difficult to follow needs that difficulty identified before its effect can be interpreted.

## Include symptoms and daily function

Appetite changes, gastrointestinal symptoms and ability to maintain food and fluid intake matter. Semaglutide's label describes nausea, vomiting, diarrhea and other adverse effects, including dehydration-related kidney injury. [2]

A lower number on the scale is not the only relevant finding if treatment is also causing persistent symptoms. Conversely, stable weight after earlier loss may need a different discussion from no meaningful benefit since starting.

## A switch needs a specific reason

NIDDK describes several possible responses when a weight-management plan is not working as intended, including reviewing lifestyle support, other medicines and alternative treatment. Switching is one option, not a conclusion produced by the word “plateau.” [1]

Tirzepatide has its own contraindications, adverse effects and reproductive considerations. Its dual-receptor mechanism does not eliminate those questions. [3]

## Avoid an improvised transition

The prescribing provider should determine whether to continue, change or stop treatment and give product-specific instructions. The labels caution against combining these products with other GLP-1 medicines. [2][3]

The review should leave a clear reason for the next step and a date to reassess its effects.

## Sources
[1] Prescription Medications to Treat Overweight & Obesity - NIDDK. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[2] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[3] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support